Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis

Heart

Volumn 100, Issue 15, 2014, Pages 1165-1172

  Ise, Takayuki ^a   Hasegawa, Takuya ^a   Morita, Yoshiaki ^a   Yamada, Naoaki ^a   Funada, Akira ^a   Takahama, Hiroyuki ^a   Amaki, Makoto ^a   Kanzaki, Hideaki ^a   Okamura, Hideo ^a   Kamakura, Shiro ^a   Shimizu, Wataru ^a   Anzai, Toshihisa ^a   Kitakaze, Masafumi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; PREDNISOLONE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEATH; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; LATE GADOLINIUM ENHANCEMENT; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SARCOIDOSIS; STEROID THERAPY; SURVIVAL RATE;

MYOCARDIAL DISEASE;

CARDIOMYOPATHIES; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; GADOLINIUM DTPA; GLUCOCORTICOIDS; HEART VENTRICLES; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING, CINE; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PREDNISONE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SARCOIDOSIS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84904058137     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-305187     Document Type: Article

References (29)

1. James DG, Neville E, Carstairs LS. Bone and joint sarcoidosis. Semin Arthritis Rheum 1976;6:53-81.
2. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine 1999;78:65-111. (Pubitemid 29153026)
3. Shammas RL, Movahed A. Sarcoidosis of the heart. Clin Cardiol 1993;16:462-72. (Pubitemid 23164232)
4. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993;103:253-8. (Pubitemid 23027268)
5. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119:167-72.
6. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-90. (Pubitemid 40704507)
7. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
8. Smedema JP, Snoep G, van Kroonenburgh MP, et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 2005;128:1629-37. (Pubitemid 41324457)
9. Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005;26:1461-74. (Pubitemid 41373486)
10. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501-11.
11. Hiraga H, Yuwai K, Hiroe M. Guideline for the diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases (in Japanese). Tokyo, Japan: The Japanese Ministry of Health and Welfare, 1993:23-4.
12. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
13. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated gfr from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92.
14. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long- Term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10. (Pubitemid 33042612)
15. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. (Pubitemid 41821197)
16. Amano Y, Kumita S, Takayama M, et al. Comparison of contrast-enhanced MRI with iodine-123 BMIPP for detection of myocardial damage in hypertrophic cardiomyopathy. AJR Am J Roentgenol 2005;185:312-18.
17. Kono AK, Yamada N, Higashi M, et al. Dynamic late gadolinium enhancement simply quantified using myocardium to lumen signal ratio: normal range of ratio and diffuse abnormal enhancement of cardiac amyloidosis. J Magn Reson Imaging 2011;34:50-5.
18. Bondarenko O, Beek AM, Hofman MB, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson 2005;7:481-5. (Pubitemid 40563339)
19. Gao P, Yee R, Gula L, et al. Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ Cardiovasc Imaging 2012;5:448-56.
20. Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long- Term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005;95:143-6. (Pubitemid 40051133)
21. Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013;309:896-908.
22. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1977-85. (Pubitemid 44738448)
23. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:867-74.
24. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-87.
25. Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010;3:51-8.
26. Butler CR, Kumar A, Toma M, et al. Late gadolinium enhancement in cardiac transplant patients is associated with adverse ventricular functional parameters and clinical outcomes. Can J Cardiol 2013;29:1076-83.
27. Motoyasu M, Kurita T, Onishi K, et al. Correlation between late gadolinium enhancement and diastolic function in hypertrophic cardiomyopathy assessed by magnetic resonance imaging. Circ J 2008;72:378-83. (Pubitemid 351600629)
28. Leong DP, Chakrabarty A, Shipp N, et al. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J 2012;33:640-8.
29. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.